NCT06826313 A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
| NCT ID | NCT06826313 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Guangzhou Virotech Pharmaceutical Co., Ltd. |
| Condition | Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 12 participants in total. It began in 2025-03-19 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Eligibility Criteria
Inclusion Criteria: 1. Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures. 2. Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female. 3. Subjects are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment. 4. Subjects have at least one measurable lesion. 5. ECOG score of 0 to 28 days prior to first dose of IMP. 6. An expected survival time of ≥ 12 weeks. 7. Have sufficient organ function. 8. Female patients of childbearing potential with a negative serum pregnancy test within 7 days prior to first dose of study drug. 9. Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose. Exclusion Criteria: 1. Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP. 2. Subject has previously received oncolytic virus or other gene drug therapy. 3. Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of IMP. 4. Subject is known to have an allergic reaction to any of the components of IMP. 5. Women who are breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06826313 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06826313 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06826313 currently recruiting?
Yes, NCT06826313 is actively recruiting participants. Contact the research team at clinicaltrialinfo@virot.cn for enrollment information.
Where is the NCT06826313 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06826313 clinical trial?
NCT06826313 is sponsored by Guangzhou Virotech Pharmaceutical Co., Ltd.. The trial plans to enroll 12 participants.